Silence Therapeutics Plc ADR (SLN)
NASDAQ
Closed
Oct 20, 2026
Day's Range
19.5752 wk Range
4.19Overview - SLN - Silence Therapeutics Plc ADR
Key Statistics
Valuation
Enterprise Value
393.91M
P/E (Trailing)
‪-4.75‬
P/E (Forward)
‪-25.39‬
PEG Ratio
‪0.09‬
Price / Sales (TTM)
‪975.26‬
Price / Book
‪11.85‬
EV / EBITDA
‪-6.16‬
Profitability
Profit Margin
‪61.53%‬
Operating Margin
‪-10,475.61%‬
Return on Assets
‪-29.64%‬
Return on Equity
‪-90.40%‬
Ownership
Shares Outstanding
141.73M
Float
37.85M
Short % of Shares Outstanding
‪5.02%‬
Held by Insiders
‪7.96%‬
Held by Institutions
‪44.60%‬
Price stats
Beta
‪1.44‬
50-Day Avg
‪12.51‬
200-Day Avg
‪8.29‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
7 analysts
Average price target
‪$ 33.00‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SLN - Silence Therapeutics Plc ADR
Peers - SLN - Silence Therapeutics Plc ADR
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SLNNASDAQSilence Therapeutics Plc ADR558.14MMarket Cap+28.95%52-week change-4.75P/E (Trailing)‪61.53%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - SLN - Silence Therapeutics Plc ADR
About
Silence Therapeutics Plc ADR is a biotechnology company focused on developing RNA-based medicines that use short interfering RNA, or siRNA, to regulate the activity of specific genes. Silence Therapeutics Plc ADR is working across hematology, cardiovascular disease, and rare diseases, with a pipeline that includes…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
